Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05931276 · ClinicalTrials.gov registry record · Phase 3
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
A Phase 3 study of End Stage Renal Disease and End-Stage Kidney Disease, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,540
- Enrollment target
- 8
- Study locations
NCT05931276 is a Phase 3 study of End Stage Renal Disease and End-Stage Kidney Disease that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 2,540 participants, above the 804-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (216% higher). The trial reports 8 study locations across 8 states.
The verdict
NCT05931276, a Phase 3 study of End Stage Renal Disease and End-Stage Kidney Disease, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,540 participants
- Enrollment target
- 8
- Study locations
Study Summary
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
Conditions Studied
Interventions
- DRUG Metoprolol Succinate
- DRUG Carvedilol
Study Locations (8)
California
- VA Long Beach Healthcare System, Long Beach, CA - Long Beach
Florida
- North Florida/South Georgia Veterans Health System, Gainesville, FL - Gainesville
Georgia
- Atlanta VA Medical and Rehab Center, Decatur, GA - Decatur
Iowa
- Iowa City VA Health Care System, Iowa City, IA - Iowa City
Massachusetts
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA - Boston
Minnesota
- Minneapolis VA Health Care System, Minneapolis, MN - Minneapolis
Nebraska
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE - Omaha
New Mexico
- New Mexico VA Health Care System, Albuquerque, NM - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,540 participants |
| Start Date | 2024-05-22 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05931276
The ClinicalTrials.gov registry entry for NCT05931276 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 2,540 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 804-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (216% higher). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 2 interventions - of which Metoprolol Succinate is the first listed.
NCT05931276 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05931276 about?
NCT05931276 is a clinical study titled "CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes". The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-...
What is the current status of trial NCT05931276?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,540 participants. The study started on 2024-05-22. Estimated completion is 2028-12-31.
What conditions does trial NCT05931276 study?
This clinical trial studies the following conditions: End Stage Renal Disease, End-Stage Kidney Disease.
What interventions are being tested in trial NCT05931276?
The interventions under investigation include: Metoprolol Succinate (DRUG), Carvedilol (DRUG).
Who is sponsoring clinical trial NCT05931276?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05931276 being conducted?
This trial has 8 study locations across California, Florida, Georgia, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
RECRUITING · Phase 3
-
Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
COMPLETED · Phase 3
-
A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
COMPLETED · Phase 3
-
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
COMPLETED · Phase 3
-
Prevention of Kidney Transplant Rejection
COMPLETED · Phase 3
-
An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.